News
Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted
EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share
EQS-News: Sartorius closes fiscal 2024 with very good fourth quarter and positive trend; full-year guidance achieved
EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2
EQS-News: Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
Prediction: NASA's Big Moon Mission Hiccup Will Cost Boeing Another $4 Billion in 2025
File today's space story under the lyric, "Second verse, same as the first."
It's been nearly six years now since President Trump (v1.0) announced plans to land Americans on the moon in 2024 under
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the
Sonova HY 2025/26 Results: Strong sales and earnings growth in local currencies, outperforming the market
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery
Sonova expands AI leadership with innovations debuting at EUHA 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the
EQS-News: BB Biotech to be included in the SPI ESG Index
Eric Bernard takes over as Sonova CEO effective September 15, 2025
Sonova expands Infinio range and enters new market segment with Phonak’s smallest and first rechargeable in-the-ear hearing aid
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled
LivaNova to Announce Second-Quarter 2025 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and reminds
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable